93 related articles for article (PubMed ID: 36453626)
1. Costs of biomarker testing among patients with metastatic lung or thyroid cancer in the USA: a real-world commercial claims database study.
Hess LM; Michael D; Krein PM; Marquart T; Sireci AN
J Med Econ; 2023; 26(1):43-50. PubMed ID: 36453626
[TBL] [Abstract][Full Text] [Related]
2. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
[No Abstract] [Full Text] [Related]
3. Effect of Clinical Trial Participation on Costs to Payers in Metastatic Non-Small-Cell Lung Cancer.
Merkhofer C; Chennupati S; Sun Q; Eaton KD; Martins RG; Ramsey SD; Goulart BHL
JCO Oncol Pract; 2021 Aug; 17(8):e1225-e1234. PubMed ID: 34375561
[TBL] [Abstract][Full Text] [Related]
4. Cost sharing for oral lenvatinib among commercially insured patients.
Liang MI; Chen L; Aviki EM; Wright JD
Am J Manag Care; 2024 Mar; 30(3):114-117. PubMed ID: 38457819
[TBL] [Abstract][Full Text] [Related]
5. Out-of-Pocket Costs for Patients Undergoing Thyroid Surgery.
Zheng F; Huang Y; Wright J; Kuo JH
Ann Surg; 2022 Dec; 276(6):e937-e943. PubMed ID: 34261887
[TBL] [Abstract][Full Text] [Related]
6. Patient out-of-pocket costs for suspicious pulmonary nodule biopsy in lung cancer patients.
Zheng F; Lavin J; Sprafka JM
J Med Econ; 2021; 24(1):1173-1177. PubMed ID: 34596001
[TBL] [Abstract][Full Text] [Related]
7. The cost burden of metastatic prostate cancer in the US populations covered by employer-sponsored health insurance.
Horný M; Yabroff KR; Filson CP; Zheng Z; Ekwueme DU; Richards TB; Howard DH
Cancer; 2023 Oct; 129(20):3252-3262. PubMed ID: 37329254
[TBL] [Abstract][Full Text] [Related]
8. The healthcare resource utilization and costs of chronic lung allograft dysfunction following lung transplantation in patients with commercial insurance in the United States.
Sheshadri A; Sacks NC; Healey B; Cyr P; Boerner G; Huang HJ
J Med Econ; 2022; 25(1):650-659. PubMed ID: 35502563
[TBL] [Abstract][Full Text] [Related]
9. Commercial claims costs related to health care resource use associated with a diagnosis of peanut allergy.
Shaker M; Chalil JM; Tran O; Vlahiotis A; Shah H; King T; Green TD; Greenhawt M
Ann Allergy Asthma Immunol; 2020 Apr; 124(4):357-365.e1. PubMed ID: 31954759
[TBL] [Abstract][Full Text] [Related]
10. Frequency and Costs of Out-of-Network Bills for Outpatient Laboratory Services Among Privately Insured Patients.
Sen AP; Meiselbach MK; Wang Y; Eisenberg MD; Anderson GF
JAMA Intern Med; 2021 Jun; 181(6):834-841. PubMed ID: 33900358
[TBL] [Abstract][Full Text] [Related]
11. Economic Burden of Checkpoint Inhibitor Immunotherapy for the Treatment of Non-Small Cell Lung Cancer in US Clinical Practice.
Nesline MK; Knight T; Colman S; Patel K
Clin Ther; 2020 Sep; 42(9):1682-1698.e7. PubMed ID: 32747004
[TBL] [Abstract][Full Text] [Related]
12. Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer.
Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
Oncologist; 2019 Sep; 24(9):1209-1218. PubMed ID: 30796156
[TBL] [Abstract][Full Text] [Related]
13. Healthcare resource utilization and costs 2 years pre- and post-lumbar spine surgery for stenosis: a national claims cohort study of 22,182 cases.
Koltsov JCB; Sambare TD; Alamin TF; Wood KB; Cheng I; Hu SS
Spine J; 2022 Jun; 22(6):965-974. PubMed ID: 35123048
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Value and Cost-Effectiveness of Next-Generation Sequencing-Based Testing for Treatment of Patients with Advanced/Metastatic Non-Squamous Non-Small-Cell Lung Cancer in the United States.
Zou D; Ye W; Hess LM; Bhandari NR; Ale-Ali A; Foster J; Quon P; Harris M
J Mol Diagn; 2022 Aug; 24(8):901-914. PubMed ID: 35688357
[TBL] [Abstract][Full Text] [Related]
15. Costs associated with the use of multigene panel tests in three solid tumor types and the impact on insurance premiums.
Wong W; Sheinson D; Liu Y; To TM
Future Oncol; 2023 Mar; 19(10):705-714. PubMed ID: 37070428
[No Abstract] [Full Text] [Related]
16. Trends in Health Care Expenditures and Patient Out-of-Pocket Expenses in Primary Anterior Cruciate Ligament Reconstruction.
Carbone AD; Wang K; Tiao J; Chu B; Poeran J; Colvin AC; Gladstone JN; Anthony SG
Am J Sports Med; 2022 Aug; 50(10):2680-2687. PubMed ID: 35834951
[TBL] [Abstract][Full Text] [Related]
17. Health insurance coverage and switching among people with hemophilia A in the United States.
He C; Hinds D; Pezalla E; Cheng D; Chen E; Sammon J; Solari PG; Recht M
J Manag Care Spec Pharm; 2022 Feb; 28(2):232-243. PubMed ID: 34780299
[No Abstract] [Full Text] [Related]
18. Use and Costs for Tumor Gene Expression Profiling Panels in the Management of Breast Cancer From 2006 to 2012: Implications for Genomic Test Adoption Among Private Payers.
Roberts MC; Dusetzina SB
J Oncol Pract; 2015 Jul; 11(4):273-7. PubMed ID: 26105668
[TBL] [Abstract][Full Text] [Related]
19. Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring
Stargardter M; McBride A; Tosh J; Sachdev R; Yang M; Ambavane A; Mittal M; Vioix H; Liu FX
J Med Econ; 2021; 24(1):816-827. PubMed ID: 34126842
[TBL] [Abstract][Full Text] [Related]
20. Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.
Dalal AA; Guerin A; Mutebi A; Culver KW
J Med Econ; 2018 Jul; 21(7):649-655. PubMed ID: 29516752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
